Menu
SENS PubMed Publication Search
LAMP2A as a therapeutic target in Parkinson disease.
Xilouri M, Brekk OR, Kirik D, Stefanis L
Abstract:
.....One of the main pathways for SNCA degradation is chaperone-mediated autophagy (CMA), a selective form of autophagy, while aberrant SNCA may act as a CMA inhibitor. In the current punctum we summarize our recent data showing that induction of CMA, via overexpression of the protein controlling its rate-limiting step, the lysosomal receptor LAMP2A, effectively decreases SNCA levels and ameliorates SNCA-induced neurodegeneration, both in neuronal cell culture systems and in the rat brain.....
PMID: 24145820
SENS Approach:
